Deyang Stomatological Hospital

Two compounds, including one new alkaloid, namely, aspergilloid A (1), together with one known compound (2), were isolated from the sponge-derived fungus Aspergillus sp. MF01. The structure of one undescribed compound was elucidated by NMR, HRESIMS, and electronic circular dichroism (ECD) diffraction spectroscopy. All the isolated compounds were evaluated for their antimicrobial activities. Compound 1 showed weak antibacterial activity against Gram-positive bacteria Staphylococcus aureus and Staphylococcus epidermidis at 1 mg/mL.

Cerebral palsy (CP) is the leading cause of childhood motor disability, often requiring intensive, long-term rehabilitation to improve motor function and independence in daily activities. Robot-assisted therapy has emerged as a promising intervention, as it can deliver high-intensity, task-specific, and motivating treatment. However, evidence for its superiority over conventional rehabilitation interventions (CRIs) is inconsistent, and a comprehensive quantitative synthesis is lacking. This protocol details a systematic review and meta-analysis to evaluate the effectiveness of robot-assisted therapy on motor outcomes in children with CP. This protocol has been developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement. We will conduct a comprehensive search of five electronic databases (PubMed, Embase, Web of Science, CINAHL, and the Cochrane Library) from their inception to June 2025. The review will include randomized controlled trials (RCTs) comparing robot-assisted therapy with CRIs in children with CP. Two independent reviewers will screen titles, abstracts, and full texts and extract relevant data. Primary outcomes will include measures of gross motor function, activities of daily living (ADL), gait, and balance. Secondary outcomes will include upper limb function and quality of life. Where appropriate, we will perform a meta-analysis using a random-effects model in Stata 14.0. We will investigate sources of heterogeneity using subgroup and sensitivity analyses. Publication bias will be assessed with funnel plots and Egger's test. Furthermore, Trial Sequential Analysis will be employed to assess the robustness of the findings and control for risks of random error. The overall quality of evidence will be evaluated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. PROSPERO CRD420250652267.

BackgroundAtherosclerosis (AS) is a leading cause of cardiovascular-related death worldwide. The role and regulatory mechanism of GAS6-AS2 in AS remain unclear.AimTo investigate the diagnostic/prognostic value of GAS6-AS2 in AS and clarify its molecular mechanism.Methods107 AS patients and 105 healthy controls were included. The levels of GAS6-AS2, miR-138-5p, and mRNA were measured using RT-qPCR. ROC curve, K-M survival analysis, and Cox regression were performed to evaluate the diagnostic and prognostic value of GAS6-AS2. Bioinformatics prediction and dual-luciferase reporter assay were performed to verify the regulatory axis. Ox-LDL-induced VSMCs were used to construct an AS cell model. The biological functions were assessed using CCK-8, SA-β-Gal, and ELISA.ResultsGAS6-AS2 expression was significantly increased in AS patients and in VSMCs treated with ox-LDL, and it showed high diagnostic accuracy and risk prediction for patients with AS. Knockdown of GAS6-AS2 reduced SA-β-Gal-positive cells, downregulated the expression of senescence-related genes and proteins (p16, p21, p53), and decreased the levels of inflammatory factors (IL-6, IL-1β) in ox-LDL-induced VSMCs. Mechanistically, GAS6-AS2 directly bound to miR-138-5p and inhibited its expression, while miR-138-5p targeted AKT1 to suppress its expression. Rescue experiments confirmed that the GAS6-AS2/miR-138-5p/AKT1 axis mediated ox-LDL-induced VSMC senescence and inflammation.ConclusionsGAS6-AS2 is a potential diagnostic and prognostic biomarker for AS. It regulates ox-LDL-induced VSMC senescence and inflammatory response through the sponging of miR-138-5p to upregulate AKT1, providing a novel molecular target for AS treatment.Supplementary InformationThe online version contains supplementary material available at 10.1186/s41065-026-00650-5.

BackgroundPneumonia remains a leading cause of global mortality. Patients receiving glucocorticoid therapy represent a particularly vulnerable subgroup due to therapy-induced immunosuppression, which complicates diagnosis and worsens prognosis. The platelet-to-neutrophil ratio (PNR), a composite hematologic index, has shown prognostic utility in various diseases, but its value in glucocorticoid-treated pneumonia patients remains unexplored.MethodsThis multicenter retrospective cohort study utilized data from 686 hospitalized pneumonia patients receiving systemic glucocorticoids, extracted from the Dryad database. The association between admission PNR and all-cause in-hospital mortality at 30 and 90 days was assessed using Cox proportional hazards models. Receiver operating characteristic curves were used to evaluate predictive performance.ResultsIn-hospital mortality within both 30 and 90 days decreased significantly with increasing PNR tertiles (Tertile 1 vs. Tertile 3: 37.55% vs. 9.61% for 30-day; 43.67% vs. 10.92% for 90-day). In fully adjusted models, each standard deviation increase in PNR was associated with a 50% reduction in 30-day in-hospital mortality [Hazard Ratio (HR) = 0.497, 95% CI 0.262–0.942] and a 58% reduction in 90-day in-hospital mortality (HR = 0.416, 95% CI 0.218–0.793). Compared to the lowest tertile, the highest PNR tertile was associated with a 76% lower risk of 30-day mortality (HR = 0.235, 95% CI 0.107–0.513) and an 82% lower risk of 90-day mortality (HR = 0.184, 95% CI 0.085–0.398). PNR demonstrated superior predictive ability (areas under the curve for 30-day: 0.707; 90-day: 0.713) compared to platelet or neutrophil count alone. Subgroup analysis revealed stronger associations in patients receiving high-dose glucocorticoids and those with diabetes or hypertension.ConclusionA lower PNR at admission is independently associated with increased short-term mortality in pneumonia patients receiving glucocorticoids. PNR, as a readily available biomarker, may facilitate early risk stratification and identify high-risk patients who could benefit from more aggressive management.